Jianhui Yang

Jianhui Yang

Auto-generated profile, based on publicly available information

Jianhui Yang

School of Pharmacy Anhui Medical University Hefei China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in BMEMat
Verified
Journal Article
Open access
QLQi Liu
Qi Liu
JYJianhui Yang
Jianhui Yang
YXYumeng Xing
Yumeng Xing
YZYu Zhao
Yu Zhao
YLYang Liu
Yang Liu
The clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR‐related protein 9 (Cas9) genome editing system has attracted much attention due to its powerful genome editing capacity. However, CRISPR‐Cas9 components are easily degraded by acids, enzymes, and other substances in the body fluids after entering the organism, thus efficiently delivering the CRISPR‐Cas9 system into targeted organs or cells has been a central theme for promoting the application of CRISPR‐Cas9 technology. Although several physical methods and viral vectors have been developed for CRISPR‐Cas9 delivery, their clinical application still suffers from disadvantages, such as the risks of mutagenesis, cell damage, and poor specificity. As an alternative, non‐viral nanocarriers hold great promise for circumventing these challenges. Furthermore, with aim to realize more efficient and precise genome editing and reduce the undesirable side effects, stimuli‐responsive nanocarriers are designed for the spatiotemporal CRISPR‐Cas9 delivery in responsive to various stimuli. In this review, we will summarize the recent progress in delivery strategies for CRISPR‐Cas9 genome editing. The mechanisms and advantages of these strategies were reviewed, providing a comprehensive review of the rational design of materials and techniques for efficient and precise genome editing. At last, the potential challenges of current CRISPR‐Cas9 delivery are discussed.

16 April 2025 in Chemical Engineering Journal
Verified
Journal Article
Closed access
YWYunlong Wang
Yunlong Wang
MWMengting Wang
Mengting Wang
JYJianhui Yang
Jianhui Yang
MLMengxia Liang
Mengxia Liang
HLHeqing Liu
Heqing Liu
DTDasheng Tian
Dasheng Tian

5 October 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
LZLianxiao Zhang
Lianxiao Zhang
JYJianhui Yang
Jianhui Yang
JPJinli Pang
Jinli Pang
QDQijie Diao
Qijie Diao
YSYanguo Su
Yanguo Su
XZXia Zhao
Xia Zhao
Lactate, as a key metabolite in the tumor microenvironment (TME), has been reported to inhibit the stimulator of interferon genes (STING) pathway and contribute to immunosuppression and tumor progression. Here, we develop a dual‐enzyme delivery system (Fuc@ZIF‐GOx‐LOx, FZGL) that is coated with fucoidan (Fuc) and loaded with glucose oxidase (GOx) and lactate oxidase (LOx) based on zinc imidazolate framework‐90 (ZIF‐90), to inhibit breast cancer metastasis by “source interception and downstream blockade” of lactate. FZGL targets tumor cells via Fuc and releases GOx and LOx by the ATP‐responsive degradation of ZIF‐90. GOx rapidly consumes glucose to block lactate generation from the source (“source interception”) and induces disulfidptosis in tumor cells. LOx degrades accumulated lactate (“downstream blockade”) to alleviate immunosuppression. FZGL activates the cGAS‐STING pathway by damaging mitochondria and inducing mitochondrial DNA (mtDNA) release. Furthermore, lactate depletion can relieve lactate‐mediated inhibition of STING signaling, thereby enhancing the anti‐tumor immune response. In vivo experiments demonstrate that FZGL significantly promotes T cell infiltration and M1 macrophage polarization, and effectively inhibits the growth and lung metastasis of breast cancer. Our study provides a new approach for metastatic breast cancer treatment through lactate metabolism intervention.

23 July 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
JYJianhui Yang
Jianhui Yang
APAo Peng
Ao Peng
SLShuaiqiang Li
Shuaiqiang Li
YHYaning Huang
Yaning Huang
JYJian Yan
Jian Yan
QLQi Liu
Qi Liu
Engineered bacteria have emerged as a promising therapeutic modality but face safety risks and delivery challenges in clinical practice. Herein, we develop a programmable encapsulation technology that formulates individual bacteria with a thin formulation layer of cross‐linked polymers, which confers live bacteria with reduced immunogenicity and restricted proliferation in healthy organs. To leverage these benefits, an engineered Escherichia coli Nissle strain capable of converting tumor‐accumulated ammonia into L‐arginine and secreting soluble programmed cell death protein 1 (sPD‐1) was encapsulated to synthesize a degradable bacterial capsule, optimizing both biosafety and delivery processes while preserving therapeutic function. Upon reaching the tumors, matrix metalloproteinase‐2 triggers bacterial release and local proliferation, achieving L‐arginine‐driven tumor immune microenvironment modulation and sustained PD‐L1 blockade, ultimately initiating robust antitumor immune responses. Overall, this programmable encapsulation platform tackles both safety risks and delivery challenges of bacterial medicines, broadening the clinical application prospects of live bacterial therapeutics.

22 September 2026 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
LWLeyuan Wang
Leyuan Wang
JYJianhui Yang
Jianhui Yang
YLYang Liu
Yang Liu
QLQi Liu
Qi Liu